Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRAX
SellHot AirPraxis Precision Medicines, Inc. · Healthcare · United States · $9.6B · Avg Vol: $132M/d
COMPANY DESCRIPTION
Praxis Precision Medicines, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system (CNS) disorders. Its drug pipeline targets conditions such as epilepsy, movement disorders, and depression by addressing neuronal excitation-inhibition imbalance. The company distinguishes itself through a precision medicine approach, aiming to provide targeted treatments for patients with high unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2.4M | 8.6M | 0 | 249.5% | — | 0.9M | 348.0M | 244.0% |
| EPS | -8.22 | -5.89 | -10.21 | -13.48 | — | -12.95 | -13.94 | -9.29 | — |
| Shares | 27.9M | 27.9M | 19.4M | 25.2M | -9.6% | 27.9M | — | — | — |
| Debt | 3.5M | 2.5M | 1.4M | 0.1M | -68.4% | 1.1M | — | — | — |
| Equity | 76.1M | 69.7M | 445.4M | 878.1M | 126.0% | — | — | — | — |
| Op CF | -185.0M | -111.1M | -131.8M | -249.1M | — | -305.1M | — | — | — |
| Inv CF | 96.9M | 39.0M | -248.5M | -311.1M | — | — | — | — | — |
| Fin CF | 10.5M | 91.9M | 514.3M | 702.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRAX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRAX | Praxis Precision Medicines, Inc.(you) | $9.6B | 31 | Sell |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 32 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.3B | 31 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 21 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%